QUANTUM GENOMICS news, videos and press releases
For more news please use our advanced search feature.
QUANTUM GENOMICS - More news...
QUANTUM GENOMICS - More news...
- Quantum Genomics announces that it has obtained the approval of Shareholders on the reduction of its share capital and on the contribution in kind of 100% of ExactCure's securities.
- Quantum Genomics publishes its results for the 2023 financial year. The merger with ExactCure, which marks the strategic redeployment of the company and will be submiCed for a shareholder vote on April 24.
- Quantum Genomics enters into exclusive negotiations with ExactCure
- Quantum Genomics Releases First-Half 2023 Financial Results
- Quantum Genomics announces resuming discussions with HealthTech companies following the termination of exclusive negotiations with Vistacare Medical
- Quantum Genomics enters into exclusive negotiations with Vistacare Medical with the ambition of creating a reference player in the management of complex wounds
- Quantum Genomics releases its 2022 financial results and provides an update on its MandA discussions
- Quantum Genomics announces reorganization of its Board of Directors and staff restructuration in order to focus on new projects
- Quantum Genomics gives an update
- Quantum Genomics Announces Lack of Significant Efficacy for Firibastat in Their Phase III Study, FRESH and is Redirecting to New Developments
- Quantum Genomics announces lack of significant efficacy for firibastat in their phase III study, FRESH and is redirecting to new developments
- Quantum Genomics Announces the Next Meeting of its Scientific and Clinical Committee
- Bryan Garnier and Co Initiates the Coverage of Quantum Genomics with a Target Price at 13 EUR per Share
- Bryan Garnier & Co Initiates the Coverage of Quantum Genomics with a Target Price at 13€ per Share
- Quantum Genomics Publishes its 2022 First Half Results and Reviews its Activity
- Quantum Genomics Publishes its 2022 First Half Results and Reviews its Activity
- Quantum Genomics Announces That the Results Obtained with Firibastat in its Phase III Study, FRESH Will Now be Presented on November 7, 2022, During the AHA Conference in a Session Dedicated to Resistant Hypertension
- Quantum Genomics announces that it will present the results from its phase III FRESH study on difficult-to-treat and resistant hypertension at the annual American Heart Association (AHA) conference on November 4 , 2022
- Quantum Genomics (ALQGC): Initiation — A fresh take on cardiovascular medicine
- Quantum Genomics announces the appointment of its new Scientific Advisory Board
- Quantum Genomics announces the appointment of its new Scientific Advisory Board
- Quantum Genomics Announces the End of Patient Recruitment for its Phase III Pivotal Study FRESH
- Quantum Genomics Announces the End of Patient Recruitment for its Phase III Pivotal Study FRESH
- Quantum Genomics Appoints Sarah Merlen Boulenger as Head of Regulatory Affairs
- Quantum Genomics Appoints Sarah Merlen Boulenger as Head of Regulatory Affairs
- Publication of the Universal Registration Document
- Quantum Genomics publishes its results for fiscal 2021 and gives an update on its activity
- Update of Shareholding Situation Following April 27, 2022 Capital Raise
- Quantum Genomics announces successful capital raising with a gross sum of approximately EUR 15.6 M EUR
- Quantum Genomics Raises a Gross Amount of Approximately EUR 15 M